louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01793363: Tracheostomy and Weaning From Mechanical Ventilation : Evaluation of the Lung Ultrasound Score
Official title: Tracheostomy and Weaning From Mechanical Ventilation : Evaluation of the Lung Ultrasound Score
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Tracheotomy
Keywords: Tracheotomy
Weaning from mechanical ventilation
Lung ultrasound score
Lead sponsor: University Hospital, Clermont-Ferrand
Sponsor class: OTHER
Collaborators: name: Groupe Hospitalier Pitie-Salpetriere
First posted: 2013-02-15
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: Prospective, interventional multicentric study in ICU during weaning from mechanical ventilation in tracheotomized patients

Detailed description: Prospective multicentric study on ICU evaluating Lung Ultrasound Score in tracheotomized patients during weaning from mechanical ventilation

Eligibility criteria: Inclusion Criteria:

* Adult patients tracheotomised during ICU stay
* Consent of patients

Exclusion Criteria:

* Tracheotomy before ICU
* No echogenicity

Primary outcomes:
measure: Variation of lung ultrasound score
timeFrame: at day 1
Secondary outcomes:
measure: Time to weaning from mechanical ventilation
timeFrame: at day 1
measure: Length of hospital stay
timeFrame: Day 1 + 90 days
Other outcomes:
Locations:
city: Clermont-Ferrand
country: France
facility: CHU Clermont-Ferrand
Study officials:
affiliation: University Hospital, Clermont-Ferrand
name: Sébastien PERBET
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06732063: Evaluation of Postoperative Pain After Endodontic Retreatment Using Different Working Length Determination Methods: A Randomized Clinical Trial
Official title: Evaluation of Postoperative Pain After Endodontic Retreatment Using Different Working Length Determination Methods: A Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: This Study Compares the Effects of Two Working Length Methods on Postoperative Pain in Single-rooted, Single-canal Teeth During Root Canal Retreatment
Lead sponsor: TC Erciyes University
Sponsor class: OTHER
First posted: 2024-12-13
Enrollment: 64
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The aim of this study is to compare the effects of two different working length determination methods on the incidence of postoperative pain in single-rooted, single-canal teeth undergoing root canal retreatment (RCR). Sixty-four previously treated, single-rooted, single-canal teeth, which were determined to require RCR based on clinical symptoms and radiographic findings, were randomly and equally divided into two groups and included in the study. Two distinct working mechanisms of an integrated endodontic motor with an apex locator were used in our study. One method involved simultaneous determination of the working length during canal shaping, while the other method determined the working length with a hand file after the canal filling was removed. After the session in which the methods were applied and the working length was determined, participants' pain levels were recorded using a visual analog scale (VAS) at 6-12 hours and on days 1-2-3-4-5-6-7.


Eligibility criteria: Inclusion Criteria:

Healthy volunteers aged between 18 and 65 with no systemic diseases. Teeth without acute apical abscess. Single-rooted and single-canal teeth that have previously undergone root canal treatment, failed, and require re-treatment (diagnosed based on clinical symptoms and radiographic findings).

Individuals with preoperative pain rated 50 or lower on the 100 mm VAS scale

Exclusion Criteria:

Individuals with systemic diseases or allergic reactions. Pregnancy and breastfeeding. Teeth with open apex. Teeth with internal or external root resorption. Patients who have taken analgesic, anti-inflammatory, or antibiotic medications within the last twelve hours.

Teeth with broken instruments in the canal. Individuals with bruxism problems.

Primary outcomes:
measure: Evaluation of different working length measurement methods in endodontic treatment and postoperative pain.
timeFrame: 7 days
Secondary outcomes:
Other outcomes:
Locations:
city: Kayseri
country: Turkey
facility: Erciyes University
state: Talas
Study officials:
References:
Clinical trial NCT03523663: System for Determining Ideal Drug Doses for ADHD - Stages 1 and 2
Official title: Algorithm to Quantitatively Determine the Ideal Drug Dose to Treat Attention Deficit Hyperactivity Disorder
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Attention Deficit Hyperactivity Disorder
Lead sponsor: University of Wisconsin, Madison
Sponsor class: OTHER
First posted: 2018-05-14
Enrollment: 46
Sex: ALL
Minimum age (years): 8
Maximum age (years): 12
Standard ages: CHILD
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: children

Brief summary: The goal of this study is to create a formal, quantitative methodology to determine what is the most beneficial dose of Central Nervous System (CNS) stimulant (Ritalin, methylphenidate) to improve cognitive and behavioral function of children diagnosed with Attention Deficit Hyperactivity Disorder (ADHD) individually. If successful, it will change the way in which the dose of CNS stimulant for treating ADHD is determined for children in need of therapeutic intervention. The project will be focused on developing the necessary methodology to analyze the children's data with the drift-decision model (DDM), and to develop the required technology, i.e., a computer game with which to measure cognitive/behavioral function and its validation with eye-tracking measurements.


Eligibility criteria: Inclusion Criteria:

* 8-12 years of age;
* Accompanied by caregiver (parent or legal guardian);
* Able to understand and speak English;
* Able to read basic English;
* No counseling or current/past history of psychiatric illness, as confirmed by the Child Behavior Checklist (CBCL) and Conner's rating scale

Exclusion Criteria:

* Active psychosis or suicidality
* History of primary psychotic disorder (e.g., schizophrenia) or bipolar disorder
* Recent (past 2 weeks) substance abuse or dependence
* History of brain damage or significant developmental delay
* Unstable medical condition such as newly diagnosed Type I Diabetes or Rheumatoid arthritis
* Use of oral steroids
* Participation in the last 30 days in a clinical study involving an investigational drug
* Current use of a psychotropic medicine

Primary outcomes:
measure: Task choice
timeFrame: At the time of testing (the investigators are measuring acute effects, not following outcomes based on a treatment)
measure: Reaction time
timeFrame: At the time of testing (the investigators are measuring acute effects, not following outcomes based on a treatment)
measure: Eye position
timeFrame: At the time of testing (the investigators are measuring acute effects, not following outcomes based on a treatment)
Secondary outcomes:
Other outcomes:
Locations:
city: Madison
country: United States
facility: Wisconsin Institutes of Medical Research
state: Wisconsin
Study officials:
affiliation: University of Wisconsin, Madison
name: Luis C Populin, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00759863: LifeZig Personalized Reminiscence Video With Slideshows and Music for Individuals With Alzheimer's and Dementia
Official title: LifeZig System for Individuals With Alzheimer's Disease
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Alzheimer's Disease
Dementia
Lead sponsor: Photozig, Inc.
Sponsor class: INDUSTRY
First posted: 2008-09-25
Enrollment: 242
Sex: ALL
Minimum age (years): 21
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The LifeZig Project is a research study of a new reminiscence activity for individuals with Alzheimer's Disease (AD) and other types of dementia, based on the LifeZig system, with personalized video channels containing old photographs and music on television.

The goal of the LifeZig study is to enhance the quality of life for dementia patients and their families/caregivers, decrease the burden of care, and contribute to positive interaction between dementia patients and families/caregivers.

Detailed description: This program creates personalized TV channels with old photographs of AD patients, music, narration and relaxing sounds; as an activity to relax dementia patients.

Eligibility criteria: Inclusion Criteria:

* Inclusion criteria for dementia patients:

  * documented diagnosis of probable Alzheimer's or other type of dementia, medically stable, and visual/hearing capabilities to watch television.
* Inclusion criteria for family members/caregivers:

  * provide care or be a family member of dementia patient, have knowledge of the person, and be able to provide old photographs of dementia patient.

Primary outcomes:
measure: Multidimensional Observation Scale for Elderly Subject
timeFrame: 6 months
Secondary outcomes:
measure: Revised Memory and Behavior Problems Checklist
timeFrame: 6 months
measure: Center for Epidemiologic Studies Depression Scale
timeFrame: 6 months
Other outcomes:
Locations:
city: Moffett Field
country: United States
facility: Photozig, Inc.
state: California
Study officials:
affiliation: Photozig, Inc.
name: Bruno Kajiyama, MS
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01178463: Spermatogonial Stem Cells in Azoospermic Patients: a Comparison Between Obstructive and Non-obstructive Azoospermia
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Male Infertility
Lead sponsor: Hillel Yaffe Medical Center
Sponsor class: OTHER_GOV
First posted: 2010-08-10
Enrollment: 25
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Infertile male patients treated at the Hillel Yaffe Medical Center IVF Unit

Brief summary: The researchers hypothesized that nonobstructive azoospermia might be associated with a reduction OF SSCs in seminiferous tubules as compared with obstructive azoospermia. Testicular sperm specimens that had been previously extracted from azoospermic patients will be paraffin embedded and stained with anti GPR-125. After antigen retrieval, the sections will be incubated with rabbit anti GPR125 followed by Cy3-conjugated anti rabbit secondary antibodies. Those found to be SSCs will be counted using light microscopy, and compared between patients with obstructive (n=11) and non-obstructive azoospermia (n=9).


Eligibility criteria: Inclusion Criteria:

* Azoospermic patients

Exclusion Criteria:

* Patients with sperm cells

Primary outcomes:
measure: SSCs were identified in both obstructive and nonobstructive azoospermia patients.
timeFrame: One year
Secondary outcomes:
Other outcomes:
Locations:
city: Hadera
country: Israel
facility: Hillel Yaffe Medical Center - IVF Unit
Study officials:
References:
Clinical trial NCT01749163: Hyperglycemia and the Extra-pancreatic Effect of Incretins
Official title: Determining the Extra-pancreatic Effects of Incretin Hormones During Euglycemic and Hyperglycemic Pancreatic Clamps
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Extra-pancreatic Incretin Effect
Glucose Effectiveness
Lead sponsor: Rigshospitalet, Denmark
Sponsor class: OTHER
First posted: 2012-12-13
Enrollment: 20
Sex: MALE
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: Incretin hormones (GLP-1 and GIP) released from the intestine in response to meal ingestion augment insulin secretion from the pancreas to help maintain glycemic control. Studies in vitro and in vivo have shown that these incretin hormones also have functional effects in other tissues independent of the insulin secretory response. Both GLP-1 and GIP stimulate insulin secretion in a glucose-dependent manner, however the glucose-dependency of their extra-pancreatic effects has not been examined in vivo. By using pancreatic clamp methodology during euglycemic and hyperglycemic conditions we will test the hypothesis that extra-pancreatic effects of GLP-1 and GIP are glucose-dependent.


Eligibility criteria: Inclusion Criteria:

* age 18-60 years
* BMI 18-30 kg/m2
* Male
* Normal glycemic control (fasting glucose \<5.6 mM)

Exclusion Criteria:

* Evidence of chronic disease
* Smoking
* Active weight loss (\>2 kg in previous 6 months)
* Treatment with drugs known to affect our outcome varaibles

Primary outcomes:
measure: Glucose metabolism
timeFrame: up to 4 hours
measure: Lipid metabolism
timeFrame: up to 4 hours
Secondary outcomes:
measure: Endothelial function
timeFrame: Baseline, 2 hours, and 4 hours
measure: Signaling
timeFrame: Baseline, 2 hours, and 4 hours
Other outcomes:
Locations:
city: Copenhagen
country: Denmark
facility: Rigshospitalet
state: Capital Region
Study officials:
affiliation: Rigshospitalet, Denmark
name: Thomas PJ Solomon, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01546363: Tissue and Plasma Biomarkers of Lymph Node Involvement in Cervical Cancer
Official title: Tissue and Plasma Biomarkers of Lymph Node Involvement in Cervical Cancer
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Cervical Cancer
Lead sponsor: Stanford University
Sponsor class: OTHER
First posted: 2012-03-07
Enrollment: 95
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Recruitment of patients for participation in this study will occur at Stanford Medical Center. All facilities are adequately equipped to meet all study requirements. Patients of this disease type are regularly treated at Stanford Cancer Center. Estimated accrual rates are based on normal patient flow.

Brief summary: The purpose of this study is to measure the levels of serum proteins and other biomarkers in cervical cancer patients. We believe that some of these markers may be useful in selecting patients for specific types of cancer therapies. These markers may also help to predict response to therapy, relapse after therapy, and survival after therapy.

Detailed description: SPECIFIC STUDY AIMS

Specific Aim 1: To use gene expression analysis of primary cervical cancers to identify a gene expression signature that predicts for lymph node metastases in this disease.

Specific Aim 2: To predict lymph node metastases by performing multiplex measurements of cancer-associated proteins and cytokines using proximity ligation assay (PLA) on plasma samples.

Specific Aim 3: To measure circulating human papilloma virus (HPV) DNA in the plasma samples of cervical cancer patients using real-time quantitative polymerase chain reaction (qPCR) and determine its ability to predict for nodal metastases.

Specific Aim 4: To use deep sequencing to evaluate gene and sequence differences between cervical cancer patients with and without lymph node metastasis.

Eligibility criteria: Inclusion Criteria:

* Patients must have a known or suspected cervical cancer.
* Age \>=18 years.
* Patients must have no other active cancer at the time of diagnosis.
* Patients must have no history of a hysterectomy.
* Patients must be able to give informed consent.
* Patients must be willing to undergo a biopsy of the cervical tumor to provide tissue for the study.
* Patients must have completed a standard-of-care FDG-PET/CT prior to initiation of therapy, for assessment of lymph nodes.

Exclusion Criteria:

- Pregnant women

Primary outcomes:
measure: Biomarkers (genes and proteins) of lymph node involvement
timeFrame: 4 years
Secondary outcomes:
Other outcomes:
Locations:
city: Stanford
country: United States
facility: Stanford University, School of Medicine
state: California
Study officials:
affiliation: Stanford University
name: Elizabeth Kidd, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02083263: Non Invasive Ventilation as Airway Clearance in Patients With Cystic Fibrosis
Official title: Study of Non Invasive Ventilation With High Pressure as Airways Clearance Technique in Adults Patients With Cystic Fibrosis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cystic Fibrosis
Keywords: Lung function
Lead sponsor: Karolinska University Hospital
Sponsor class: OTHER
Collaborators: name: Karolinska Institutet
First posted: 2014-03-11
Enrollment: 32
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: With the use of Non invasive ventilation the patients with cystic fibrosis will have better lung function (FEV1).

Detailed description: 3 months intervention between PEP an Bilevel. The patients will follow up under 3 months.

Eligibility criteria: Inclusion Criteria:

* Patients with CF older than 18 years
* FEV1 between 20% and 69% of predictive.
* No acute exacerbation.
* No Burkhordelia Cepacia/MRSA colonization.

Exclusion Criteria:

* Children under 18 year
* acute exacerbation.

Primary outcomes:
measure: Lung Function: Lung Clearance Index
timeFrame: up to 3 months
Secondary outcomes:
measure: Blood Gases:1 Month After Chest Physiotherapy Will Take Blood Gases (Kpa).
timeFrame: 1 month
Other outcomes:
Locations:
city: Stockholm
country: Sweden
facility: Cecilia Rodriguez
Study officials:
affiliation: Karolinska Institutet
name: Cecilia Rodriguez, Physio
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04490863: Noninvasive Hemoglobin Repeatability and Reproducibility in a Blood Donation Setting
Official title: Noninvasive Hemoglobin Spot Check Repeatability and Reproducibility in a Blood Donation Setting
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy
Anemia
Lead sponsor: Masimo Corporation
Sponsor class: INDUSTRY
First posted: 2020-07-29
Enrollment: 26
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: The primary objective of this clinical investigation is to report on the repeatability and reproducibility of SpHb measurements from Rad-67 devices and DCI Mini sensors used to screen prospective blood donors at a donation center.


Eligibility criteria: Inclusion Criteria:

* At least 18 years of age
* Weight at least 110 pounds
* Subjects with the intention of being screened for eligibility to donate blood
* The subject has given written informed consent to participate in the study

Exclusion Criteria:

* Subjects with skin abnormalities at the planned application sites that may interfere with sensor application, per directions-for-use (DFU) or trans-illumination of the site, such as burns, scar tissue, infections, abnormalities, etc.
* Subjects unwilling to remove nail polish or acrylic nails
* Subjects with blood cancers such as leukemia
* Subjects with hemoglobin disorders such as sickle-cell anemia and thalassemia or with known history of infectious diseases such as HIV/AIDS, syphilis, hepatitis, etc.
* Subjects with self-disclosed/known pregnancy at the time of enrollment
* Subjects deemed not suitable for the study at the discretion of the investigator
* Subjects unlikely to be able to refrain from excessive motion during data collection. Excessive motion includes postural changes, making hand gestures, involuntary muscular movements, etc.

Primary outcomes:
measure: Coefficient of Variation of Rad-67
timeFrame: Approximately 90 minutes per subject
Secondary outcomes:
Other outcomes:
Locations:
city: San Diego
country: United States
facility: Blood Bank - Site 1
state: California
Study officials:
References:
Clinical trial NCT05884463: 18F-FAPI PET Imaging in Pancreatic Adenocarcinoma
Official title: 18F-FAPI PET/CT and 18F-FDG PET/CT in Patients With Pancreatic Adenocarcinoma : A Prospective, Single-Center, Comparative Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: 18F-FAPI
18F-FDG
Pancreas Adenocarcinoma
Diagnosis
Staging
Lead sponsor: Zhejiang University
Sponsor class: OTHER
First posted: 2023-06-01
Enrollment: 62
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: To explore the potential efficacy of 18F-FAPI-04 PET/CT for PDAC tumour staging and compare the results with those obtained using 18F-FDG PET/CT.

Detailed description: Accurate diagnosis and staging are crucial for selecting treatment for patients with pancreatic ductal adenocarcinoma (PDAC). The desmoplastic responses associated with PDAC are often characterised by hypometabolism. Here we investigated 18F-fibroblast activation protein inhibitor (18F-FAPI-04) positron emission tomography/computed tomography (PET/CT) in evaluation of PDAC, and compared the findings with those obtained using (18F)-fluorodeoxyglucose (18F-FDG).

Eligibility criteria: Inclusion Criteria:

patients who were suspected to have PDAC by radiological imaging patients who underwent paired 18F-FAPI-04 PET/CT and 18F-FDG PET/CT for metastasis screening, recurrence confirmation, or tumour staging patients who were willing to participate in clinical trials and signed an informed consent form.

Exclusion Criteria:

patients with a history of severe contrast allergy pregnant patients patients who were not pathologically diagnosed as showing PDAC.

Primary outcomes:
measure: Diagnostic value
timeFrame: 1 day (At the time the patient has underwent both 18F-FAPI and 18F-FDG PET/CT)
measure: Maximum standardized uptake value
timeFrame: 1 day (At the time the patient has underwent both 18F-FAPI and 18F-FDG PET/CT)
Secondary outcomes:
measure: Diagnostic efficacy for primary lesions
timeFrame: 1 day (At the time the patient has underwent both 18F-FAPI and 18F-FDG PET/CT)
measure: SUVmax for primary lesions
timeFrame: 1 day (At the time the patient has underwent both 18F-FAPI and 18F-FDG PET/CT)
measure: SUVmax for lymph node
timeFrame: 1 day (At the time the patient has underwent both 18F-FAPI and 18F-FDG PET/CT)
measure: SUVmax for distant metastasis
timeFrame: 1 day (At the time the patient has underwent both 18F-FAPI and 18F-FDG PET/CT)
measure: Correlation between the SUVmax of 18F-FAPI and 18F-FDG uptake in patients with different treatment response
timeFrame: at least 2 months after treatment
Other outcomes:
Locations:
city: Hangzhou
country: China
facility: the First Affiliated Hospital, School of Medicine, Zhejiang University
state: Zhejiang
Study officials:
affiliation: Zhejiang University
name: Tingbo Liang, Ph.D., M.D.
role: STUDY_DIRECTOR
References: